TouchRESPIRATORY got the opportunity to catch up with Alyn Morice (University of Hull, Castle Hill Hospital, Yorkshire, UK) around the unmet needs and treatment of patients with chronic cough (Clinical Trial Identifier: NCT03449134 & NCT03449147).
The abstract ‘Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2).’ (ABSTRACT NUMBER: 188) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions
- What are the unmet needs in the treatment of people with refractory or unexplained chronic cough (RCC/UCC)? (0:20)
- How did you assess cough triggers and symptoms among patients with RCC and UCC? (1:35)
- Â What were the aims and design of the COUGH-1 and COUGH-2 studies, and what were the findings? (2:34)
- What is the mechanism of action of Gefapixant? (3:57)
- How can we use these findings to address the unmet needs of people with chronic cough? (4:55)
Disclosures: Alyn Morice has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
